Shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) have been given an average rating of “Buy” by the twenty-four research firms that are currently covering the company, MarketBeat reports. One analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and nineteen have given a buy recommendation to the company. The average 1 year price target among analysts that have updated their coverage on the stock in the last year is $155.11.
A number of brokerages have recently issued reports on ALXN. BidaskClub cut Alexion Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Friday, February 2nd. Evercore ISI raised shares of Alexion Pharmaceuticals from an “in-line” rating to an “outperform” rating in a research report on Monday. Raymond James Financial reaffirmed an “outperform” rating and set a $130.00 price target (down previously from $178.00) on shares of Alexion Pharmaceuticals in a research report on Thursday, January 4th. They noted that the move was a valuation call. Leerink Swann reaffirmed a “buy” rating and set a $169.00 price target on shares of Alexion Pharmaceuticals in a research report on Wednesday, December 6th. Finally, Credit Suisse Group reaffirmed an “outperform” rating and set a $147.00 price target on shares of Alexion Pharmaceuticals in a research report on Thursday, January 18th.
Alexion Pharmaceuticals (NASDAQ ALXN) traded up $3.08 on Friday, hitting $117.99. The company’s stock had a trading volume of 852,694 shares, compared to its average volume of 1,895,428. Alexion Pharmaceuticals has a 1 year low of $96.18 and a 1 year high of $149.34. The firm has a market cap of $25,970.00, a P/E ratio of 52.76, a price-to-earnings-growth ratio of 0.94 and a beta of 1.16. The company has a debt-to-equity ratio of 0.35, a current ratio of 2.96 and a quick ratio of 2.51.
In related news, CEO Ludwig Hantson sold 2,553 shares of the company’s stock in a transaction dated Tuesday, January 2nd. The shares were sold at an average price of $121.63, for a total value of $310,521.39. Following the sale, the chief executive officer now owns 36,172 shares in the company, valued at approximately $4,399,600.36. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 4.35% of the company’s stock.
Institutional investors and hedge funds have recently bought and sold shares of the stock. Wealthsource Partners LLC boosted its stake in Alexion Pharmaceuticals by 4.4% during the 2nd quarter. Wealthsource Partners LLC now owns 3,002 shares of the biopharmaceutical company’s stock valued at $365,000 after purchasing an additional 126 shares during the period. National Asset Management Inc. raised its position in Alexion Pharmaceuticals by 5.1% in the 2nd quarter. National Asset Management Inc. now owns 3,345 shares of the biopharmaceutical company’s stock worth $407,000 after purchasing an additional 162 shares during the period. Grandfield & Dodd LLC raised its position in Alexion Pharmaceuticals by 12.6% in the 3rd quarter. Grandfield & Dodd LLC now owns 3,785 shares of the biopharmaceutical company’s stock worth $531,000 after purchasing an additional 425 shares during the period. Bender Robert & Associates raised its position in Alexion Pharmaceuticals by 1.3% in the 4th quarter. Bender Robert & Associates now owns 32,873 shares of the biopharmaceutical company’s stock worth $3,931,000 after purchasing an additional 430 shares during the period. Finally, Piedmont Investment Advisors LLC raised its position in Alexion Pharmaceuticals by 1.0% in the 2nd quarter. Piedmont Investment Advisors LLC now owns 46,533 shares of the biopharmaceutical company’s stock worth $5,662,000 after purchasing an additional 446 shares during the period. Institutional investors own 94.04% of the company’s stock.
ILLEGAL ACTIVITY WARNING: This piece was first reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this piece on another website, it was copied illegally and reposted in violation of US and international copyright and trademark laws. The legal version of this piece can be read at https://www.dispatchtribunal.com/2018/02/14/alexion-pharmaceuticals-inc-alxn-receives-154-16-consensus-target-price-from-analysts.html.
About Alexion Pharmaceuticals
Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).
Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.